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Design of a synthetic Mdm2-binding mini protein that activates
the p53 response in vivo
Angelika Böttger, Volker Böttger, Alison Sparks, Wei-Li Liu, Stephanie F.
Howard and David P. Lane
Background: The transcriptional activation function of the p53 tumour
suppressor protein is induced by DNA damage and results in growth arrest
and/or apoptotic responses. A key component of this response is the dramatic
rise in p53 protein concentration resulting from an increase in the protein’s
stability. Very recently, it has been suggested that interaction with the Mdm2
protein may target p53 for rapid degradation. We have designed a gene
encoding a small protein that binds tightly to the p53-binding pocket on the
Mdm2 protein. We have constructed the gene by cloning a phage display
optimised Mdm2-binding peptide into the active-site loop of thioredoxin. 
Results: When introduced into cells containing low levels of wild-type p53, this
protein causes a striking accumulation of the endogenous p53 protein,
activation of a p53-responsive reporter gene, and cell cycle arrest mimicking
the effects seen in these cells after exposure to UV or ionising radiation.
Microinjection of a monoclonal antibody to the p53-binding site on Mdm2
achieves a similar effect, establishing its specificity.
Conclusions: These results demonstrate that the p53 response is constitutively
regulated in normal cells by Mdm2 and that disruption of the interaction alone is
sufficient to stabilise the p53 protein and activate the p53 response. Our mini
protein approach provides a powerful new method to activate p53 without
causing DNA damage. More broadly, it establishes a powerful general method
for determining the biological consequences of the specific disruption of
protein–protein interactions in cells.
Background
When normal cells or tissues containing low levels of
wild-type p53 are exposed to DNA-damaging agents, the
p53 protein accumulates and p53-responsive gene tran-
scription is enhanced. The response can induce both cell
cycle arrest and apoptosis, and studies comparing wild-
type with p53-null mice suggest that this activation of
p53 is a key step in the normal biological response to
radiation [1,2]. The mechanism of this accumulation of
p53 protein is post-translational and results from regula-
tion of the normally rapid degradation of the protein [3].
Earlier reports have suggested that p53 function might
be controlled in part by the oncogene Mdm2 [4–6]. This
is due to an autoregulatory feedback loop for p53 activity
involving Mdm2. Mdm2 is transcriptionally activated by
binding of p53 to an internal promoter within the Mdm2
gene [7,8]. Mdm2 then binds the amino terminus of p53,
thereby preventing p53 from interacting with the tran-
scriptional machinery [9,10]. The most impressive support
for the importance of this autoregulatory loop in main-
taining cell survival comes from experiments with trans-
genic mice. Mdm2–/– mice are viable only in the absence
of p53 [11,12]. This shows that the level of p53 activity
has to be tightly controlled in early development and
that Mdm2 is a key component of this control pathway.
Very recently it has been shown in transient transfection
assays that the Mdm2 protein can target p53 for degrada-
tion by the ubiquitin system [13,14]. If this pathway
operates constitutively in cells containing low levels of
p53, then interruption of the p53–Mdm2 interaction
should lead to accumulation of p53 and activation of p53-
responsive reporter genes. We have designed a gene that
encodes a small protein that binds tightly to the p53-
binding pocket of Mdm2. This was achieved by express-
ing a phage display optimised Mdm2-binding peptide on
the surface of bacterial thioredoxin. The mini protein is
able to block very efficiently the interaction of p53 and
Mdm2 in vitro. Introduction of the mini protein into cells
with normal low levels of wild-type p53 leads to a dra-
matic accumulation of the endogenous p53 protein and
activation of p53-responsive reporter genes. This protein–
protein interaction-blocking mini protein thus provides
clear evidence that p53 levels and activity are continu-
ously down-regulated by Mdm2 in the absence of a
damage response. It provides a powerful tool to study the
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p53 response as it allows activation of a cell’s endoge-
nous p53 protein in the absence of DNA damage. This
approach can be widely applied to study other protein–
protein interactions.
Results
Designing a synthetic protein that binds Mdm2 at the 
p53-binding pocket
We constructed the gene encoding our Mdm2-binding
protein by inserting into the Escherichia coli thioredoxin
gene an oligonucleotide encoding a 12 amino acid peptide
with potent Mdm2-binding activity that we had previ-
ously identified by phage selection (peptide 12/1) [15].
This sequence occupies the p53-binding pocket of Mdm2,
thereby competing with native p53 for binding to Mdm2
[16]. This novel gene was designed so that the Mdm2-
binding peptide would be displayed at the surface of
thioredoxin as an in-frame insert into the active-site loop
of the protein. Thioredoxin provides an excellent scaffold
for protein design because of its stability and ready expres-
sion in prokaryotic and eukaryotic cells and because inser-
tion at the active-site loop inactivates its intrinsic bio-
chemical function [17]. The new protein was designated
SuperTIP (thioredoxin insert protein). We constructed
controls for the activity of SuperTIP by cloning the Mdm2-
binding domain of wild-type p53 into the same site (wild-
type TIP) and, using knowledge of the crystal structure
of the p53 wild-type peptide bound to Mdm2 [18], we
designed a mutant SuperTIP protein in which the key
contact residues on the p53 site, Phe19, Trp23 and Leu26,
were mutated to alanine (SuperTIP-Ala, see Figure 1).
Thioredoxin alone (Trx) was used as a third control.
All of these proteins, collectively referred to as ‘TIPs’,
were expressed in E. coli and purified from soluble heat
shock bacterial lysates to approximately 80% homogene-
ity. Alternatively, the chimeric proteins were purified to
near homogeneity from soluble bacterial lysates, which
were not heat shocked, by ion exchange chromatography
and gel filtration. Results obtained with TIPs purified
each way were identical. 
We tested the TIPs for their capacity to inhibit the p53–
Mdm2 interaction in ELISA assays. Binding of glutathione-
S-transferase (GST)–Mdm2 (1–188) to p53-coated ELISA
plates was inhibited by increasing amounts of bacterially
expressed TIPs. Table 1 shows their inhibitory potential
as IC50 values obtained in this assay in comparison with
the IC50 for the corresponding peptides and bacterially
expressed full-length p53.
A number of important conclusions can be drawn from
these data. Firstly, SuperTIP inhibits the interaction
between p53 and Mdm2 in this assay with the same
strength as full-length p53, suggesting that it will compete
effectively against endogenous levels of wild-type p53
for binding to Mdm2. Secondly, wild-type TIP inhibits
the interaction 50 times less than SuperTIP, consistent
with the 20 times less potent inhibition achieved by the
wild-type p53 peptide when compared with peptide 12/1
in peptide competition assays. Finally, neither Trx nor
the SuperTIP-Ala control protein show inhibition in our
assay, making both of these reagents suitable negative
controls for in vivo experiments. These results demon-
strate that it is possible to express Mdm2-binding pep-
tides derived from phage display in an effective binding
conformation by virtue of an in-frame insertion into the
active-site loop of thioredoxin. 
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Figure 1
Schematic representation of the mini proteins wild-type TIP, SuperTIP
and SuperTIP-Ala showing the p53 wild-type sequence or the phage-
derived peptide inserted between Gly33 and Pro34 of E. coli
thioredoxin. The amino acids essential for Mdm2 binding are
underlined in SuperTIP and replaced by alanines in SuperTIP-Ala. The
three-dimensional structure for thioredoxin was obtained from the
Protein Data Bank (PDB), Brookhaven National Laboratory, and
displayed using the public domain program RasMol.
C32
G33
P34
C35
Wild-type TIP    PPLSQETFSDLWKLLPENG
SuperTIP    PPLSMPRFMDYWEGLNENG
SuperTIP-Ala PPLSMPRAMDYAEGANENG
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Table 1
Inhibitory potentials of thioredoxin insert proteins (TIPs)
compared with free peptides and full-length p53 in p53–Mdm2
binding assays.
Inhibitor IC50 (nM)
Wild-type TIP 15,000
SuperTIP 300
Thioredoxin (Trx) No inhibition
SuperTIP-Ala No inhibition
Wild-type p53 peptide 2000
Peptide 12/1 100
Full-length p53 400
Expression of TIPs in mammalian cells activates 
p53-dependent transcription
SuperTIP, wild-type TIP, thioredoxin and SuperTIP-Ala
were expressed under the control of the cytomegalovirus
(CMV) promoter in mammalian cells. We asked initially
whether a stably transfected p53-responsive β-galactosi-
dase reporter could be switched on by microinjecting the
plasmids encoding the TIPs. For these experiments, we
used a recently established transformed rat thyroid epithe-
lial cell line (VRn.6 cells) stably transfected with pRGC∆-
Fos-lacZ as a p53-responsive reporter. It has been shown
before that these cells tolerate high levels of wild-type p53
and overexpress Mdm2 at the protein level [19]. In addi-
tion, the β-galactosidase reporter is strongly responsive to
UV induction of p53 in VRn.6 cells, demonstrating an
intact p53-response pathway. Furthermore, previous work
had shown that microinjection of the Mdm2-binding mono-
clonal antibody 3G5 into the nuclei of these cells could
switch on the p53 reporter [19]. Interestingly, we have
recently demonstrated, in vitro, that 3G5 binds Mdm2
exactly within the p53-binding pocket and blocks p53–
Mdm2 association [15]. If the effect of 3G5 injection on
the induction of p53-dependent transcription in these
cells was due to interrupting the p53–Mdm2 interaction,
our inhibiting TIP proteins should exert a similar effect.
Injecting the SuperTIP-encoding plasmid into the nuclei of
VRn.6 cells (Figure 2c) resulted in the dramatic induction
of the reporter enzyme when assayed 24 h after injection
by direct histochemical staining. There was no induction
after microinjection of the control thioredoxin-encoding
plasmid (Figure 2d) or SuperTIP-Ala (not shown), although
staining after micoinjection with anti-thioredoxin antibod-
ies shows that these mini proteins are clearly expressed. We
confirmed the strong induction of β-galactosidase activity
after microinjection of 3G5 into the nuclei of VRn.6 cells
(Figure 2a). To be certain that the cells that responded with
β-galactosidase activity were the injected ones, we carried
out dual immunofluorescence studies. We stained cells
after injection with anti-β-galactosidase antiserum and with
anti-mouse immunoglobulin. Figure 2b shows that the cells
expressing the reporter enzyme (left-hand panel, blue) are
also positive for the injected antibody (right-hand panel,
green). This remarkable result validates the use of the syn-
thetic mini protein as a specific p53-activating agent. 
Several arguments establish the specificity of its action
and support the conclusion that it acts by disrupting the
p53–Mdm2 interaction. The failure of the alanine mutant
control to activate p53 is a very powerful proof for the
specificity of SuperTIP as it establishes a clear structure–
function relationship. A perhaps even stronger argument
comes from the combined use of the monoclonal antibody
3G5. That we should achieve exactly the same result with
these two very different agents — one delivered as an
expression construct, the other as a pure protein, one a
monoclonal antibody with its binding site on the edge of
the p53-binding pocket, the other a novel synthetic
protein designed to fill the pocket and each appropriately
controlled — establishes beyond reasonable doubt that
these agents act by a common mechanism.
We have, therefore, now developed a specific tool to
disrupt cellular pathways that depend on the p53–Mdm2
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Figure 2
VRn.6 cells after microinjection with
monoclonal anti-Mdm2 antibody 3G5 or TIPs.
(a) Detection of β-galactosidase activity in
cells microinjected with 3G5 by X-gal
substrate development. (b–d) Confocal
images of dual immunofluorescence after
microinjecting 3G5 (b) or plasmids encoding
SuperTIP (c) or Trx (d). Left-hand panels (in
blue) show β-galactosidase expression by
staining with rabbit anti-β-galactosidase
antiserum and FITC-conjugated anti-rabbit Ig;
right-hand panels (in green) show successful
injection of 3G5 by staining with Texas red
conjugated anti-mouse Ig or successful
expression of TIPs by staining with Anti-ThioTM
followed by Texas red conjugated anti-mouse
Ig. (Scale bar = 50 µm.)
interaction. A number of human tumours exist in which
high levels of wild-type p53 are tolerated in the presence of
elevated levels of Mdm2, caused either by gene amplifica-
tion, elevated mRNA [20], or enhanced translation [21].
The VRn.6 cell line can be considered a model for such
tumour cells in that it has high levels of p53 as well as
Mdm2 [19]. The first impetus for our efforts to develop
inhibitors of the Mdm2–p53 interaction had, therefore,
been to try to release these high levels of p53 from their
constraint by Mdm2 and so to induce p53-dependent tran-
scription in this subset of human tumour cells. Recent evi-
dence suggests that a Mdm2-dependent pathway of p53
degradation may act in cells with normal low levels of
Mdm2 [13,14]. According to this model, interruption of the
interaction between the two proteins should also have an
effect in cells with low levels of Mdm2. We therefore
carried out microinjection experiments with 3G5 and
SuperTIP in T22 cells, a mouse prostate derived cell line,
also stably transfected with the same β-galactosidase
reporter plasmid. In contrast to VRn.6 cells, these cells
contain very low levels of wild-type p53 and Mdm2. On
treatment with DNA-damaging agents, the p53 protein
accumulates and the cells show strong p53-dependent β-
galactosidase induction [22,23]. Figure 3 shows the result of
microinjecting 3G5 and TIP-encoding plasmids into T22
cells. Again, we detect strong induction of β-galactosi-
dase with 3G5 (Figure 3a) but no induction with 4B2
(Figure 3b), an anti-Mdm2 antibody that targets an
epitope outside the p53-binding pocket on Mdm2. As
before, expression of SuperTIP induced a strong response
(Figure 3c). Lower levels of β-galactosidase activity are
observed with wild-type TIP (Figure 3d) and no activity
with the control thioredoxin (Figure 3e) or control Super-
TIP-Ala (Figure 3f). Again, this reflects the relative degree
to which the three TIPs inhibit the Mdm2–p53 interaction
in vitro (Table 1). Staining of the injected cells with anti-
thioredoxin antibody confirmed that the differences in
reporter enzyme activity were not due to differential
expression of the TIP proteins (not shown).
The strong induction of reporter enzyme in T22 cells,
which do not overexpress Mdm2, implies that release of
p53 from Mdm2 complexes is a very strong stimulus for p53
activation and can operate in cells with normal low levels of
Mdm2 and p53, similar to induction of p53 by genotoxic
insult. To give further support to this assumption, we
sought to analyse more cell lines with different levels of
Mdm2–p53 complex formation. We therefore transiently
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Figure 3
T22 cells after microinjection with monoclonal
anti-Mdm2 antibodies or TIP-encoding
plasmids. β-galactosidase activity is shown
after X-gal substrate development by blue
staining 24 h after microinjection of (a) 3G5,
(b) 4B2 (control antibody), (c–f) plasmids
encoding SuperTIP (c), wild-type TIP (d),
Trx (e; control) or SuperTIP-Ala (f; control).
transfected cells containing wild-type p53 with p53-respon-
sive reporter plasmids (RGC∆-Fos-lacZ) and SuperTIP or
Trx controls. We chose OSA cells, a human osteosarcoma
cell line [20], as an example of a cell line with highly ele-
vated Mdm2 levels due to gene amplification. We also used
U2-OS cells, another osteosarcoma cell line, which has no
gene amplification for Mdm2 but has elevated levels of
Mdm2 mRNA [20], and MCF7 cells, a breast cancer cell
line with low levels of wild-type p53 and no reported
Mdm2 elevation [24]. We confirmed the relative levels of
Mdm2 in these different cells by western blotting (data
not shown). We cotransfected reporter plasmid (RGC∆-
Fos-lacZ) together with SuperTIP- or Trx-encoding DNA
into all three cell lines. Different lipophilic transfection
agents were used and the transfection efficiency was mon-
itored on separate plates by transfecting pGL3 control, a
plasmid encoding firefly luciferase under a constitutive pro-
moter, and measuring luciferase activity. In order to directly
compare the levels of reporter enzyme induction between
all three cell lines, transfection protocols were selected for
each one to achieve equivalent expression of luciferase after
transfection of a fixed amount of pGL3 control plasmid.
Figure 4 shows induction of β-galactosidase activity by
SuperTIP compared to Trx control plasmid in each cell
line. The transfection efficiency as measured by luciferase
activity after transfection of the pGL3 control is very similar
(white bars). The greatest induction of the p53 reporter is
achieved by SuperTIP in MCF7 cells, where the level of
Mdm2 is below the detection limit in standard western
blots. A lower effect of reporter enzyme induction by
SuperTIP is observed in U2-OS cells, while in OSA cells
the induction is ~100 times lower than in MCF7 cells.
Figure 4 also shows that transfection of control Trx plasmid
alone induces a low level response of p53-dependent tran-
scriptional activation in MCF7 and U2-OS cells as seen pre-
viously [25,26]. It is, however, almost completely absent in
OSA cells.
These results confirm the concept that in cells overex-
pressing Mdm2, p53-dependent transcriptional activation
is repressed. Much more striking, however, is the obser-
vation that a reciprocal relationship exists between the
Mdm2 content of the cells and the efficiency of SuperTIP
to activate p53. Such a dose-response behaviour can be
explained by the fact that SuperTIP and p53 have a
similar affinity for binding to Mdm2. This enables Super-
TIP to compete with low and moderate levels of Mdm2
for p53 binding (MCF7 and U2-OS), but makes it much
more difficult at high Mdm2 concentrations (OSA). This
observation implies that regulation by Mdm2 is an endoge-
nous mechanism for controlling p53 activity in cells with
normal Mdm2 levels and that it is a regulatory mechanism
that can be inactivated readily by SuperTIP.
Disruption of the p53–Mdm2 interaction leads to
accumulation of p53
If Mdm2 targets p53 for rapid degradation, then disruption
of this pathway would be predicted to cause accumulation
of p53 protein. To test this hypothesis, SuperTIP or Trx
or monoclonal antibodies 3G5 or 4B2 were injected into
T22 cells and the levels of p53 analysed by immunoflu-
orescence. Figure 5 shows that p53 accumulates to high
levels in cells injected with the interaction-disrupting 3G5
antibody (Figure 5a, p53 on red panel), but not with the
control anti-Mdm2 antibody 4B2 (Figure 5b, p53 on red
panel in comparison to injected antibody on green panel).
In a similar way, cells injected with the SuperTIP expres-
sion plasmid accumulate high levels of p53 (Figure 5c,
p53 on red panel), whereas those injected with the control
plasmid Trx (Figure 5d, p53 on red panel in comparison
with expressed thioredoxin on green panel) do not. Similar
results are seen after transfection of U2-OS cells or MCF7
cells with SuperTIP-encoding plasmid. This underlines the
concept that in the absence of DNA damage, Mdm2 targets
p53 for rapid degradation and is, therefore, responsible for
its short half life. Mutant p53 proteins that cannot bind
Mdm2 should thus be more stable than wild-type p53. 
When we transfected wild-type p53 into p53-negative
SAOS2 cells, we found that cotransfection of an Mdm2
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Figure 4
Soluble β-galactosidase assays in cell lysates after transfection with
RGC∆-Fos-lacZ and SuperTIP-encoding DNA (black bars) or RGC∆-
Fos-lacZ and control Trx-encoding DNA (shaded bars). The highest
activity was measured in MCF7 cells transfected with SuperTIP and
set as 100%. To control transfection efficiencies, cells were
transfected with pGL3 control plasmid and luciferase activities are
given for each cell line (white bars).
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expression plasmid greatly reduced the level of p53 that
accumulated (Figure 6, lanes 2 and 3), an observation that
has also been described recently by Kubbutat et al. [14].
Using our knowledge of the Mdm2–p53 interaction, we
constructed a point mutation, Phe19→Ala, in murine p53
at only one of the key contact residues of the p53–Mdm2
interface identified as being essential for Mdm2 binding
both in the crystal structure and in our phage display
analysis [15,16,18]. We confirmed that this mutant p53
was unable to bind to Mdm2 but was transcriptionally
active in cotransfection assays (data not shown). When this
mutant p53 was transfected into SAOS2 cells, its accumu-
lation, unlike that of wild-type p53, was not affected by
cotransfection of the Mdm2 expression plasmid (Figure 6,
lanes 4 and 5). This lends additional evidence to the
hypothesis that direct physical contact between Mdm2
and p53 is the preposition for the rapid degradation of p53.
Interruption of this protein–protein interaction by Super-
TIP or by mutating one key contact residue on p53
increases p53 protein levels. 
The dramatic induction of the p53 response by UV and
other genotoxic agents is accompanied by the accumula-
tion of high levels of p53 protein due at least in part to its
extended half life in treated cells. Our results demon-
strate that disruption of the p53–Mdm2 interaction mirrors
the genotoxic response not only by activating p53-depen-
dent transcription but also by leading to the accumula-
tion of p53 protein. This intriguing similarity raises the
issue of whether disruption of this interaction could indeed
be the mechanism by which p53 accumulates after geno-
toxic insults.
Activation of p53 function by SuperTIP leads to cell cycle
arrest
To examine the effect of the activation of p53 by Super-
TIP on cell cycle progression, T22 cells were labelled
with bromo-deoxyuridine (BrdU) 24 h after injection.
Table 2 shows representative data from two independent
experiments. We saw a clear and specific reduction in S
phase cells among the injected population when using
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Figure 5
Confocal images showing that microinjection of (a) 3G5 or 
(c) SuperTIP-encoding plasmid into T22 cells leads to accumulation of
p53, whereas microinjection of (b) control antibody 4B2 or (d) control
Trx-encoding plasmid does not. Left-hand panels (red) show p53 levels
detected with anti-p53 antiserum CM5 and Texas red conjugated
secondary antibody. Right-hand panels (green) show staining for anti-
mouse Ig with FITC-conjugated anti-mouse Ig antibody (a,b) or for
thioredoxin with anti-ThioTM and FITC-conjugated anti-mouse Ig
secondary antibody (c,d) to confirm successful microinjection and
SuperTIP or Trx expression. (Scale bar = 50 µm.)
anti-BrdU antibodies to detect cells that were in or had
passed through S phase. Thus, activation of p53 by
SuperTIP can induce a cell cycle arrest, again establish-
ing the similarity between the damage-induced activa-
tion of p53 and the induction of p53 by disruption of the
Mdm2–p53 interaction.
Discussion
Design of synthetic mini proteins to disrupt protein–protein
interactions
In this study, we designed mini proteins able to block the
p53–Mdm2 interaction in vivo. To do this, peptide
sequences selected for tight Mdm2 binding were dis-
played on the surface of thioredoxin. They retained their
inhibitory potential in p53–Mdm2 binding assays demon-
strating the successful transfer of these sequences from
peptide to mini protein. When expressed in mammalian
cells, both mini proteins, SuperTIP and wild-type TIP,
were able to induce p53-dependent transcriptional activa-
tion of a reporter gene. The intensity of the effect exerted
by SuperTIP in comparison with wild-type TIP was pro-
portional to the in vitro inhibitory potential of the proteins.
A SuperTIP mutant protein was constructed in which
three critical contact points of the mini protein with Mdm2
were replaced by alanine, rendering this mutant SuperTIP
inactive for Mdm2 binding in vitro. This mutant mini
protein is also expressed to high levels in cells but is
unable to trigger p53 activation. This provides direct evi-
dence that the effect of SuperTIP in vivo is mediated
through its interaction with cellular Mdm2. The analysis
of the three mini proteins demonstrates a clear structure–
function relationship for their proposed mechanism of
action. With these synthetic Mdm2-binding mini pro-
teins, we have therefore developed powerful tools to
study the biological consequences of disrupting the inter-
action between Mdm2 and p53 in tumour cells. This
approach of peptide selection and mini protein design
illustrates a road leading from the identification of pep-
tides that are able to disrupt a very specific protein–
protein interaction to demonstration of the biological effect
of such disruption in vivo. This concept in combination
with the use of peptide aptamer libraries, for instance
expressed and screened in the yeast two-hybrid system
[27], should have a great potential for studying networks
of protein–protein interactions in eukaryotic cells on the
biochemical as well as on the functional level.
Activation of p53 by blocking binding to Mdm2
It had been assumed that disrupting the interaction
between p53 and Mdm2 would release transcriptionally
active p53 in tumour cells that overexpress Mdm2 due to
gene amplification. Although our experiments with OSA
cells suggest that this is true, these cells are not the most
susceptible. In contrast, MCF7 cells and U2-OS cells as
well as T22 cells, all of which have low and apparently
wild-type Mdm2 levels, respond with an immense tran-
scriptional activation of p53 after applying Mdm2-bind-
ing inhibitors. Comparison of the response in different
cell lines argues that the release of transcriptionally active
p53 is reciprocal to the Mdm2 content of the cells. Higher
affinity inhibitors, or specific targeting of our TIP pro-
teins to the nucleus, could be expected to overcome Mdm2
repression of p53 to a much higher degree in cells with
amplified Mdm2 levels, such as OSA cells. It thus appears
that the interaction of wild-type p53 with Mdm2 is the
prime restraint for p53 activity in all analysed cells. Two
very recent reports have shown that Mdm2 promotes rapid
degradation of p53 [13,14]. It was suggested that this
pathway of degradation could be responsible for the gen-
erally observed low half life of wild-type p53 in the
absence of genotoxic insults to cells. By blocking this
pathway with SuperTIP in cells with normal low Mdm2
levels, we are hereby able to prove that this pathway
operates constitutively.
Mdm2 regulates p53 levels
We show that blocking of the interaction of p53 with
Mdm2 leads to a rise in p53 protein levels. This strongly
supports a model by which Mdm2 acts as an important
upstream regulator of p53 activity by constitutively con-
trolling its degradation. As Mdm2 can be transcription-
ally activated by p53 [7,8,28], p53 effectively drives
transcription of the key regulator of its own degradation.
This provides an attractive explanation for the stabil-
ity of the p53 protein in cells in which the protein is tran-
scriptionally inactive. This includes cells that contain
only mutant p53, such as the majority of human tumour
cells and cells infected or transformed by DNA tumour
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Figure 6
Western blot of SAOS2 cell lysates 48 h after transfection with
plasmids encoding wild-type p53 (lanes 2 and 3), mutant p53
(Phe19→Ala, lanes 4 and 5) or vector alone (pcDNA3, lane 1). 
In samples 1, 3 and 5, Mdm2-encoding plasmid was cotransfected.
The blots were probed for p53 expression with rabbit antiserum
CM5.
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viruses whose products bind and inactivate the transcrip-
tional function of p53. It can be argued that these cells
lack sufficient functional Mdm2 expression to target 
p53 degradation. This is completely consistent with our
earlier finding that point mutant p53 proteins, inactive in
transcription assays, are stable when transfected into
p53-null cells but unstable in cells that contain wild-type
p53 activity [24].
If Mdm2 targets p53 for degradation, inhibition of this
interaction could prevent newly synthesized p53 from
being rapidly turned over and so lead to the observed
increase in transcriptionally active p53. The results also
imply that even in normal undamaged cells, p53 is active
as a transcription factor able to operate on the Mdm2 pro-
moter in order to maintain the feedback pathway. It is
attractive to suggest that the normal p53 response to geno-
toxic damage and other stress signals is mediated by inhi-
bition of this Mdm2 targeting of p53 for degradation.
SuperTIP is established as a novel agent able to induce
endogenous transcriptionally active p53 in the absence of
stress signals. This agent should be enormously useful in
identifying the specific p53-dependent components of
stress-response pathways. We have shown that p53 acti-
vated in this manner is still able to bring about a clear
block to cell cycle progression mimicking the cell cycle
arrest seen after DNA damage.
Conclusions
In normal proliferating cells, a pathway exists by which
p53 protein levels and activity are controlled constitu-
tively by Mdm2. If this pathway is interrupted by a
specifically designed mini protein that binds to Mdm2,
p53 accumulates and p53-dependent transcription is acti-
vated. This opens a way to induce the endogenous p53
response in the absence of a stress signal or DNA damage.
Moreover, it offers the possibility of regulating the
threshold of the p53 response pharmacologically and the
potential to develop new drugs to induce p53-mediated
apoptotic and growth-arresting responses directly and
specifically, without the complexity of inducing general
and unwanted DNA damage.
Materials and methods
Cloning and expression of TIP proteins
pTrx (Invitrogen) was cleaved with RsrII. The following oligomers were
phosphorylated, annealed and then ligated into the cleaved vector. For
wild-type TIP: 5′–3′ GTCCGCCTCTGAGTCAGGAAACATTTTCAGAC-
CTATGGAAACTACTTCCTGAAAACG and 5′–3′ GACCGTTTTCAG-
GAAGTAGTTTCCATAGGTCTGAAAATGTTTCCTGACTCAGAGGCG.
For SuperTIP: 5′–3′ GTCCGCCTCTGAGTATGCCTCGTTTTATGGAT-
TATTGGGAGGGTCTTAATGAAAACG and 5′–3′ GACCGTTTTCATT-
AAGACCCTCCCAATAATCCATAAAACGAGGCATACTCTCAGAGG
CG. For SuperTIP-Ala: 5′–3′ GTCCGCCTCTGAGTATGCCTCGTGC-
TATGGATTATGCTGAGGGTGCTAATGAAAACG and 5′–3′ GACCG-
TTTCATTAGCACCCTCAGCATAATCCATAGCACGAGGCATACTCA
GAGGCG. The resulting peptide inserts are illustrated in Figure 1.
E. coli 1724 cells were transformed with the resulting plasmids. They
were grown in RM medium at 30°C overnight, then inoculated into
fresh induction medium and grown to OD 0.5. The cultures were trans-
ferred to 37°C, induced with L-tryptophan at a final concentration of
100 µg/ml and grown for 3–4 h. Soluble extracts were obtained by
resuspending pellets in ice-cold 20 mM Tris/HCl, pH 8, 2.5 mM EDTA
with protease inhibitors (1 mM PMSF, 1 mM benzamidine, leupeptin,
approtinin and pepstatin at 10 µg/ml each) and three times shock
freezing, thawing and sonicating, followed by centrifugation for 20 min
at 10,000 g. Heat shock lysates were obtained by resuspending pellets
to an OD of 100 and then treating at 80°C for 10 min followed by cen-
trifugation at 10,000 g for 20 min.
Purification of soluble extracts was carried out by loading clear soluble
lysates onto an ion exchange Q 50 column (BioRad) and eluting with a
linear gradient of 0.05–1 M KCl in 50 mM Tris/HCl pH 7.8, 0.1% Triton
X-100, 10% glycerol and 50 mM KCl. Active fractions were identified
with anti-thioredoxin antibody (Invitrogen) on dot blots, concentrated
using Centriprep 3 filters (Amicon) and loaded onto a G100 column
(Pharmacia), preequilibrated with 30 mM HEPES, pH 8.0, 500 mM
KCl, 0.1% Triton X100, 10% glycerol. Active fractions after elution
were pooled, concentrated and dialysed against PBS.
For cloning of TIPs and Trx into pcDNA3 for expression in mammalian
cells, the complete thioredoxin-coding region with the peptide inser-
tions was amplified from pTrx, pTrx:SuperTIP, pTrx:SuperTIP-Ala and
pTrx:wild-type TIP using the following primers: 5′–3′ CGGGATC-
CACCATGGGCGATAAAATTATTCACCTG and 5′–3′ CTCGACG-
CTAACCTGGCCTAGGGAATTCC. The resulting PCR products were
cleaved with BamHI and EcoRI and ligated into BamHI–EcoRI-cleaved
pcDNA3. The SuperTIP and SuperTIP-Ala sequences in pcDNA3 were
verified by sequencing.
ELISA assays
ELISAs were carried out as previously described [15]. Briefly, plates
were coated with 1µg/ml p53 or dilutions of p53 overnight at 4°C. They
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Table 2
Number of S phase BrdU-positive cells following injection of SuperTIP-encoding or SuperTIP-Ala-encoding plasmid.
Coverslip number Plasmid injected Number of BrdU+ cells Total number of injected cells % BrdU+ cells
1 SuperTIP 13 84 15
2 SuperTIP 7 59 12
3 SuperTIP-Ala 25 64 39
4 SuperTIP-Ala 32 90 36
5 No injection 287 617 47
were blocked and a pre-incubated mixture of GST–Mdm2 (1.3µg/ml)
and synthetic peptides or TIP proteins was added for 1 h. Binding was
established with the monoclonal anti-Mdm2 antibody SMP14 [29] and
HRP-conjugated anti-mouse IgG. In peptide ELISAs, plates were coated
with streptavidin. Then, biotinylated peptide (QETFSDLWKLLP) was
added and the ELISA continued as described above.
Cell culture and microinjection
T22 cells, U2-OS cells, OSA cells and SAOS2 cells were grown in
Dulbecco’s modified Eagle medium (DMEM) supplemented with 10%
FCS; for T22 cells, 1 mg/ml G418 was added. VRn.6 cells were grown
as described previously [19].
For microinjection, cells were seeded into tissue culture dishes and
grown to 60–70% confluence. Microinjection was performed using an
Eppendorf microinjection system (Microinjector 5242, Micromanipula-
tor 5170) mounted to an Axiovert 35 M with heated stage. Antibody
injections were intranuclear or cytoplasmic. Plasmid injections were
intranuclear. Purified mouse monoclonal antibodies 3G5 and 4B2 were
injected in PBS at a concentration of ~1.3 mg/ml. Plasmid DNA encod-
ing SuperTIP, wild-type TIP, SuperTIP-Ala and Trx was purified using
Qiagen purification system or phenol/chloroform precipitation and
injected at a concentration of 0.25 mg/ml in water. Following microin-
jection, fresh medium was added to the cell cultures and they were
incubated for 24 h.
Detection of β-galactosidase activity
Cells were washed with PBS and fixed with 2% formaldehyde/0.2%
glutaraldehyde in PBS for 5 min on ice. They were again washed with
PBS and overlaid with X-gal (0.25 mg/ml) in reaction mix (5 mM potas-
sium ferricyanide, 5 mM potassium ferrocyanide, 2 mM magnesium
chloride in PBS). Cells were incubated at 37°C for 16 h. Blue-stained
cells were observed.
Immunofluorescence
VRn.6 cells were fixed with 4% paraformaldehyde in PBS for 10 min,
washed and permeabilised with 1% NP40 in PBS. Primary antibodies,
rabbit anti-β-galactosidase or monoclonal anti-thioredoxin antibody (Anti-
ThioTM Antibody, Invitrogen) were applied 1/500, FITC-conjugated goat
anti-rabbit Ig or Texas red conjugated goat anti-mouse Ig F(ab′)2 frag-
ments (Jackson) were applied 1/500 as second antibodies. Incuba-
tions were carried out for 1 h or 45 min at RT. Washes were carried
out in PBS.
T22 cells were fixed with ice-cold acetone/methanol (1:1) for 8 min at
4°C. Primary antibodies, protein A purified CM5 at 2 µg/ml or anti-
ThioTM 1/500 were added for 1 h at RT, after PBS washes Texas red
anti-rabbit Ig at 1/400 or FITC-conjugated anti-mouse Ig at 1/80 were
added for 30 min at RT.
Labelling with BrdU to detect S phase cells following
microinjection
Cells were seeded onto glass coverslips and injected with plasmid at
250 µg/ml and dextran Texas red at 2.5 mg/ml. The cells were incu-
bated for 24 h and then pulse labelled for 30 min with BrdU to label S
phase cells. The cells were then fixed and stained with anti-BrdU mon-
oclonal antibody and FITC-conjugated anti-mouse IgG. The Texas red
positive cells were then scored for BrdU incorporation. 
Transient transfections for reporter induction
Cells were seeded into six well plates at 1.5× 106 cells per well. They
were grown to a density of 80% confluence and transfected using differ-
ent lipophilic reagents (lipofectin and lipofectamin, Promega, DOSPER
and DOTAP, Boehringer). 2.5 µg TIP-encoding plasmid DNA, 1 µg
RGC∆-Fos-lacZ DNA and 5–10 µg of lipophilic reagent according to the
instructions of the manufacturers were mixed in serum-free medium and
applied to the cells. 1–4 h after transfection, complete medium was
added. 48 h after transfection, β-galactosidase activity was measured
using CPRG (Boehringer) as a substrate. Cells were scraped into PBS
and centrifuged. Pellets from each well were dissolved in 50 µl reporter
lysis buffer (Promega) and incubated on ice for 15 min. Soluble lysates
were incubated with CPRG in 100 mM phosphate buffer, pH 7.0. OD
at 595 nm was measured 1–24 h later. To measure transfection effi-
ciencies in each experiment, cells in a separate well were transfected
with 2.5 µg pGL3 DNA encoding firefly luciferase. In soluble lysates of
these cells, luciferase activity was measured using Promega’s lucifer-
ase assay system. The same lysates served as control for endogenous
β-galactosidase activity.
Transient transfections for establishing p53 levels in the
presence and absence of Mdm2
SAOS2 cells were seeded 24 h before transfection to 80% confluence
in 10 cm dishes. Calcium phosphate mediated transfections were per-
formed as previously described [30]. 5 µg of murine wild-type and
mutant p53-encoding plasmids (pcDNA3) or control vector and 5 µg
Mdm2-encoding plasmid X2 were cotransfected per 10 cm dish. 48 h
after transfection, cell lysates were fractionated by 12% SDS–PAGE
and transferred to nitrocellulose membranes. Blots were stained with
rabbit anti-p53 antiserum CM5 (1/8000) and HRP-conjugated anti-
rabbit Ig. Peroxidase activity was established using ECL.
Site-directed mutagenesis
Construction of Phe19→Ala was accomplished by site-directed muta-
genesis using the TransformerTM site-directed mutagenesis kit
(Clonetech). The sequence of the selection primer was 5′–3′
GACTCTGGGGATCGATATGACCGACC; the sequence of the muta-
genic primer was 5′–3′ GAGCCAGGAGACAGCCTCAGGCTTATG. The
sequence of the p53 mutant Phe19→Ala was confirmed by sequencing.
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